Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shoulder arthroscopy and open surgery under UK spotlight

This article was originally published in Clinica

Executive Summary

The UK has launched a study to assess the clinical and cost-effectiveness of arthroscopic and open surgery and the non-surgical ("rest then exercise") approach to tears of the shoulder's rotator cuff. Citing wide variations in clinical policy, the study commissioned by the National Coordinating Centre for Health Technology Assessment (NCCHTA) will seek to harmonise the management of what is a common cause of shoulder pain in the adult population, according to the DoH R&D body.

You may also be interested in...



Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel